anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Diclofenac
Trial phase: Phase 4
ATC code: D11AX18 | M01AB05 | M01AB55 | M02AA15 | S01BC03 | S01CC01
SMILES: O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
Eligibility criteria:
Inclusion Criteria:

A clinical diagnosis of ankylosing spondylitis (AS) by treating rheumatologists, or a diagnosis of axial spondyloarthritis (axSpA) with a pelvis MRI with significant bone marrow edema on STIR sequences;
Minimum of 18 years old;
Are taking NSAIDs on a regular basis for AS or axSpA (defined as more than 20 days in the past month) and willing to withhold medication for one week; or having active symptoms that require initiation of NSAIDs;
Concomitant anti-rheumatic drugs are allowed, if the dose has been stable for the past three months;
Have active disease after initial washout period, defined by BASDAI >=4/10, or back pain numerical rating scale (NRS)>=4/10

Exclusion Criteria:

Patients who have concurrent rheumatic diseases other than AS or axSpA;
Patients who have oral corticosteroid in the past two weeks; patients who have acute peripheral arthritis;
Patients with a fibromyalgia score >= 13;
Patient with extensive cardiac history, history of gastrointestinal bleeding that required blood transfusion, chronic kidney diseases, abnormal liver function tests; or female patients who are pregnant.

Use of low-dose of aspirin (<100mg daily) is allowed in the study.
Intervention: Dexmedetomidine Hydrochloride
Trial phase: Phase 4
SMILES: Cc1cccc(C(C)c2cnc[nH]2)c1C.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 62
Group description: 5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)

Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
Eligibility criteria:
Inclusion Criteria:

age >18, <65
scheduled for elective knee arthroscopy under spinal anesthesia
ASA I and ASA II

Exclusion Criteria:

age <18 and >65
patients who received general anesthesia
diabetes
refusal of the patient
known allergy to the specified drugs
Intervention: Magnesium Sulfate
Trial phase: Phase 4
ATC code: A06AD04 | A12CC02 | B05XA05 | D11AX05 | V04CC02
SMILES: O=S(=O)([O-])[O-].[Mg+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 62
Group description: 5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)

Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
Eligibility criteria:
Inclusion Criteria:

age >18, <65
scheduled for elective knee arthroscopy under spinal anesthesia
ASA I and ASA II

Exclusion Criteria:

age <18 and >65
patients who received general anesthesia
diabetes
refusal of the patient
known allergy to the specified drugs
Intervention: Bilastine
Trial phase: Phase 3
ATC code: R06AX29 | S01GX13
SMILES: CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 91
Group description: Bilastine Ophthalmic Solution 0.6%: 1 drop in each eye at 2 separate times during an 8 day period.
Eligibility criteria:
Inclusion Criteria:

be at least 18 years old
be willing and able to avoid all disallowed medications and contact lenses
must have a pregnancy test if of childbearing potential
must be able to read an eye chart from 10 feet away

Exclusion Criteria:

must not have any allergies to the study medications
must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
must not have used immunotherapy in the last 2 years
must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial
Intervention: Ketotifen Fumarate
Trial phase: Phase 3
SMILES: CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)C=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Ketotifen Ophthalmic Solution 0.025% (Zaditen): 1 drop in each eye at 2 separate times during an 8 day period.
Eligibility criteria:
Inclusion Criteria:

be at least 18 years old
be willing and able to avoid all disallowed medications and contact lenses
must have a pregnancy test if of childbearing potential
must be able to read an eye chart from 10 feet away

Exclusion Criteria:

must not have any allergies to the study medications
must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
must not have used immunotherapy in the last 2 years
must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial
Intervention: Prednisone
Trial phase: Phase 4
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 1
Group description: Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.

Methylprednisolone Injectable Product: 3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
Eligibility criteria:
Inclusion Criteria:

18 years of age and older,
diagnosis of stage II adhesive capsulitis as determined by clinical examination of the treating physician, and
absence of abnormal findings on X-ray.

Exclusion Criteria:

allergy to Doxycycline or Methylprednisolone,
pregnancy,
diagnosis,
Inflammatory arthritis or diabetes,
secondary adhesive capsulitis (history of significant trauma, rotator cuff tear injury, stroke)
evidence of arthritis on x-ray,
current infectious disease, and
any previous treatment for the for adhesive capsulitis of the affected shoulder.
Intervention: Pyridoxal phosphate
Trial phase: Phase 4
ATC code: A11HA06
SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 1
Group description: Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.

Doxycycline Injection: 3 intra-articular injections of Doxycycline Injection spaced every two weeks
Eligibility criteria:
Inclusion Criteria:

18 years of age and older,
diagnosis of stage II adhesive capsulitis as determined by clinical examination of the treating physician, and
absence of abnormal findings on X-ray.

Exclusion Criteria:

allergy to Doxycycline or Methylprednisolone,
pregnancy,
diagnosis,
Inflammatory arthritis or diabetes,
secondary adhesive capsulitis (history of significant trauma, rotator cuff tear injury, stroke)
evidence of arthritis on x-ray,
current infectious disease, and
any previous treatment for the for adhesive capsulitis of the affected shoulder.
Intervention: Nicotine
Trial phase: Phase 4
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.

Nicotine Replacement Therapy: Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
Eligibility criteria:
Inclusion Criteria:

UF Health cancer patients, 18 years and older, who are current smokers.

Exclusion Criteria:

Patients with unstable medical or psychiatric illness or
Patients with a use disorder for illicit drugs.
Intervention: Gefapixant
Trial phase: Phase 2
ATC code: G01AE10 | R05DB29
SMILES: COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Participants received a gefapixant 45 mg film-coated tablet twice daily for 28 days.
Eligibility criteria:
Inclusion Criteria:

Chest radiograph or computed tomography scan of the thorax (within 5 years of Screening/Visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator.
Has had chronic cough for ≥ 1 year and a diagnosis of refractory chronic cough or unexplained chronic cough.
For female participants, is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance
Provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires)

Exclusion Criteria:

Is a current smoker or has given up smoking within 12 months of Screening, or is a former smoker with a pack-year history >20 pack-years
Has a history of upper or lower respiratory tract infection or recent clinically significant change in pulmonary status
Has a history of chronic bronchitis
Is currently taking an angiotensin converting enzyme inhibitor (ACEI), or has used an ACEI within 3 months of Screening
Has a history of malignancy ≤5 years
Has a screening systolic blood pressure >160 millimeters of mercury (mmHg) or a diastolic blood pressure >90 mm Hg
Has a history of cutaneous adverse drug reaction to sulfonamides with or without systemic symptoms or history of anaphylaxis to sulfonamides
Is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence
Has a known allergy/sensitivity or contraindication to gefapixant
Has donated or lost ≥1 unit of blood within 8 weeks prior to the first dose of gefapixant
Has previously received gefapixant or is currently participating in or has participated in an interventional clinical study
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 224
Group description: Injection of 0.9% Sodium Chloride Injection, USP

Saline: Injection of 1 mL 0.9% Sodium Chloride, USP
Eligibility criteria:
Inclusion Criteria:

Age ≥ 21 and ≤ 80 years
Subject has a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren Lawrence grading scale
Subject is willing and able provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study
Subject must have a VAS pain scale greater than 45

Exclusion Criteria:

Subject has a diagnosis of osteoarthritis (OA) defined as Grade 4 on the Kellgren Lawrence grading scale
BMI greater than 40 kg/m^2
Subject has active infection at the injection site
Symptomatic OA of the contralateral knee or of either hip that is not responsive to acetaminophen (Tylenol®) and requires other therapy.
Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other disorders that is the primary source of their knee pain, including but not limited to: osteonecrosis, radiculopathy, bursitis, tendinitis, tumor, cancer
Subject has documented history of gout or pseudo-gout
Subject has autoimmune disease or a known history of having Acquired Immunodeficiency Syndromes (AIDS) or HIV

Subject has received any of the following to the target knee:

Intra-articular hyaluronic acid (HA) injection within 12 weeks prior to screening
Steroid or platelet rich plasma (PRP) injection within 12 weeks prior to screening
Has had or is planning to have major surgery or arthroscopy in the target knee within 26 weeks of treatment
History of a total knee arthroplasty
Subject has used an investigational drug, device or biologic within 12 weeks prior to treatment
Subject has a history of immunosuppressive or chemotherapy in the last 5 years
Subject has had prior radiation at the site
Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin)
Subject is pregnant or plans to become pregnant within 365 days of treatment
Subject has any significant medical condition that, in the opinion of the Investigator, would interfere with protocol evaluation and participation
Subject is a worker's compensation patient
Subject is a prisoner
Intervention: Selatogrel
Trial phase: Phase 2
SMILES: CCCCOC(=O)N1CCN(C(=O)C(CP(=O)(O)O)NC(=O)c2cc(N3CCC(OC)C3)nc(-c3ccccc3)n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: A single 8 mg dose of selatogrel (ACT-246475) was administered via a single subcutaneous injection in the thigh.
Eligibility criteria:
Main Inclusion Criteria:

Informed consent obtained prior to any study-mandated procedure,
Males aged from 18 to 85 and postmenopausal females aged up to 85 years,
Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to randomization,
Subjects presenting a type I AMI including STEMI or NSTEMI.

Main Exclusion Criteria:

Cardiogenic shock or severe hemodynamic instability,
Cardiopulmonary resuscitation,
Loading dose of any oral P2Y12 receptor antagonist prior to randomization,
Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization,
Known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand disease).
Active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding.
Known clinically important anemia.
Oral anticoagulation therapy within 7 days prior to randomization
Intervention: Selatogrel
Trial phase: Phase 2
SMILES: CCCCOC(=O)N1CCN(C(=O)C(CP(=O)(O)O)NC(=O)c2cc(N3CCC(OC)C3)nc(-c3ccccc3)n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: A single 16 mg dose of selatogrel (ACT-246475) was administered via a single subcutaneous injection in the thigh.
Eligibility criteria:
Main Inclusion Criteria:

Informed consent obtained prior to any study-mandated procedure,
Males aged from 18 to 85 and postmenopausal females aged up to 85 years,
Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to randomization,
Subjects presenting a type I AMI including STEMI or NSTEMI.

Main Exclusion Criteria:

Cardiogenic shock or severe hemodynamic instability,
Cardiopulmonary resuscitation,
Loading dose of any oral P2Y12 receptor antagonist prior to randomization,
Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization,
Known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand disease).
Active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding.
Known clinically important anemia.
Oral anticoagulation therapy within 7 days prior to randomization
Intervention: HYDROGEN PEROXIDE
Trial phase: Phase 4
ATC code: A01AB02 | D08AX01 | D11AX25 | S02AA06
SMILES: OO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: Open Label Arm

A-101 Topical Solution: A-101 Topical Solution applied Day 1, Day 15 and Day 29
Eligibility criteria:
Inclusion Criteria:

Subject can comprehend and is willing to sign an informed consent for participation in this study.
Male or female between the ages of 30 and 75 years old.
Subject has 3 eligible Seborrheic Keratoses; 2 target SKs must be on the face, and the additional 1 target SK must be on the neck or decolletage.
Subjects must have had cryosurgery for SK removal within the last 6 months and prior to first treatment with A-101 Topical Solution.
Target and non-target SKs must not have been previously treated.
Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any target or non-target SK or which exposes the subject to an unacceptable risk by study participation

Exclusion Criteria:

Subject has clinically atypical and /or rapidly growing Seborrheic Keratoses.
Subject has current systemic malignancy.
Subject would require the use of any topical treatment (e.g., moisturizers, sunscreens) to any of the target or non-target SKs 12 hours prior to any study visit.
Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
Intervention: Lixivaptan
Trial phase: Phase 2
SMILES: Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Oral high dose lixivaptan in participants with CKD1 or CKD2

Lixivaptan: Oral vasopressin V2 receptor antagonist
Eligibility criteria:
Inclusion Criteria:

Male or female, between 18 and 65 years of age at the time of screening
Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 with eGFR calculated by the CKD EPI equation
Diagnosed with ADPKD by modified Ravine criteria
Considered by Investigator to be in good health relative to underlying CKD status and clinically stable with respect to underlying CKD

Exclusion Criteria:

Known sensitivity or idiosyncratic reaction to lixivaptan, its related compounds such as benzazepines (e.g., tolvaptan, conivaptan, benazepril, fenoldopam, or mirtazapine), or any compound listed as being present in the study formulation
Women who are pregnant or breast feeding
Subjects have taken tolvaptan, oral or intravenous antibiotics, or any investigational drug or used an investigational device within 30 days or 5 half-lives, whichever is longer, prior to first study dose
Subject has a transplanted kidney, or absence of a kidney
Subjects with clinically significant incontinence, overactive bladder, or urinary retention (e.g., benign prostatic hyperplasia)
Subjects with clinically significant liver disease, or clinically significant liver function abnormalities or serology other than that expected for ADPKD with cystic liver disease at baseline
Subjects with any clinically significant concomitant disease or condition other than ADPKD (including treatment for such conditions) that, in the opinion of the Investigator, could either interfere with the study drug or pose an unacceptable risk to the subject
Intervention: Lixivaptan
Trial phase: Phase 2
SMILES: Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Oral low dose lixivaptan in participants with CKD3

Lixivaptan: Oral vasopressin V2 receptor antagonist
Eligibility criteria:
Inclusion Criteria:

Male or female, between 18 and 65 years of age at the time of screening
Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 with eGFR calculated by the CKD EPI equation
Diagnosed with ADPKD by modified Ravine criteria
Considered by Investigator to be in good health relative to underlying CKD status and clinically stable with respect to underlying CKD

Exclusion Criteria:

Known sensitivity or idiosyncratic reaction to lixivaptan, its related compounds such as benzazepines (e.g., tolvaptan, conivaptan, benazepril, fenoldopam, or mirtazapine), or any compound listed as being present in the study formulation
Women who are pregnant or breast feeding
Subjects have taken tolvaptan, oral or intravenous antibiotics, or any investigational drug or used an investigational device within 30 days or 5 half-lives, whichever is longer, prior to first study dose
Subject has a transplanted kidney, or absence of a kidney
Subjects with clinically significant incontinence, overactive bladder, or urinary retention (e.g., benign prostatic hyperplasia)
Subjects with clinically significant liver disease, or clinically significant liver function abnormalities or serology other than that expected for ADPKD with cystic liver disease at baseline
Subjects with any clinically significant concomitant disease or condition other than ADPKD (including treatment for such conditions) that, in the opinion of the Investigator, could either interfere with the study drug or pose an unacceptable risk to the subject
Intervention: Ibudilast
Trial phase: Phase 2
ATC code: R03DC04
SMILES: CC(C)C(=O)c1c(C(C)C)nn2ccccc12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 24
Group description: 20mg BID Days 1-2 50mg BID Days 3-14

Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
Eligibility criteria:
Inclusion Criteria:

Age between 21 and 45
Meet DSM-5 criteria for current Moderate-to-Severe AUD
Current Heavy Drinking (> 14 drinks per week for men; > 7 drinks per week for women), as indicated by self-reported drinking for the 30 days prior to screening
Have reliable internet access

Exclusion Criteria:

Currently receiving or seeking treatment for AUD*
Past year DSM-5 diagnosis of any substance use disorder other than alcohol or nicotine
A lifetime diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder
Current use of drugs, other than marijuana, verified by a urine toxicology screen*
Pregnant, nursing, or refusal to use reliable birth control (if female)*
A medical condition that may interfere with safe participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension, diabetes, or AST, ALT, or GGT ≥ 3 times upper normal limit)
Self-reported recent (i.e. past 30 day) use of medications that are contraindicated with ibudilast*
Non-removable ferromagnetic objects in body
Claustrophobia

Serious head injury or prolonged period of unconsciousness (>30 minutes)

Participants who meet these criteria at any point during the course of the study (i.e. after randomization) will be withdrawn from the study for safety purposes.